Navigation Links
Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
Date:4/23/2013

Valeant expects to complete the tender offer and consummate the merger promptly after the AMC's approval of the acquisition is received.  Except for the extension of the offer expiration date, all other terms and conditions of the offer remain unchanged. Stockholders who have already tendered their shares of common stock of Obagi do not have to re-tender their shares or take any other action as a result of the extension of the expiration date of the offer.

About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward Looking Statements
This press release contains forward-looking statements regarding, among other things, the proposed acquisition by Valeant of Obagi, satisfaction of closing conditions and the timing of closing.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements.  Because these statements reflect Valeant's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect the proposed business combination of the companies and could cause actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to: the risk that the acquisition will not close when expected or at all; the risk that Valeant's business and/or Obagi's business will be adversely impacted during t
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
2. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
3. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
4. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
5. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
6. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
7. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
8. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
9. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
10. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
11. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... (PRWEB) March 03, 2015 GlobalStemCellsGroup.com ... growing faculty. Camacho Alcocer, a biomedical researcher and founding ... will join GSCG’s team of biomedical professors who will ... program. , Criogenix SA de CV is a private ... Technological Institutions and Companies in Mexico (RENIECYT). , Camacho ...
(Date:3/2/2015)... York, NY (PRWEB) March 02, 2015 ... Testing Services industry has experienced robust growth. The ... consumer products, industrial materials, energy resources and other goods, ... and rising government regulation. As a result, IBISWorld forecasts ... of 2.8% to reach $946.8 million over the five-year ...
(Date:3/2/2015)... and VANCOUVER, British Columbia , ... (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical ... therapies, today announced that Craig Schneider , ... during a live webcast at VirtualInvestorConferences.com. ... http://VirtualInvestorConferences.com > click the red "register/ ...
(Date:3/2/2015)... MENLO PARK, Calif. , March 2, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, today ... year 2014 financial and operating results on Tuesday, March ... markets. The Company will host a conference call and ... Eastern / 1:30 p.m. Pacific to discuss the results ...
Breaking Biology Technology:Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 2Mario Camacho Alcocer Joins Global Stem Cells Group Faculty 3Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 2Laboratory Testing Services in Canada Industry Market Research Report Now Available from IBISWorld 3InMed Pharmaceuticals to Present Investor Webcast March 5 2Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... Officer of Neurocrine Biosciences, will be presenting at the ...   The live presentation takes place on ... 8:00 a.m. Pacific Time.  The presentation will be webcast ...
... 21, 2012  Thought leaders from the medical community in Europe ... albumin in treating liver disease and sepsis, and in cardiac ... Dialogue – "Albumin in Clinical Fluid Management ." ... participants engaged in a frank and provocative exchange about the ...
... Addario Lung Cancer Medical Institute,s research portfolio is ... platform for venture philanthropy in medical research. The ... president and COO of ALCMI, sister foundation of ... (Logo:  http://photos.prnewswire.com/prnh/20120221/DC56587LOGO ) ...
Cached Biology Technology:Medical Experts Who Participated in CSL Behring's Key Issues Dialogue Prefer Albumin for Fluid Management 2Medical Experts Who Participated in CSL Behring's Key Issues Dialogue Prefer Albumin for Fluid Management 3FasterCures Spotlights Addario Lung Cancer Medical Institute's Innovative Research Programs 2FasterCures Spotlights Addario Lung Cancer Medical Institute's Innovative Research Programs 3
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62/113114 for DISTRIBUTED METHOD AND ... The patent further establishes NXT-ID,s position in the ... property portfolio the ability for multiple devices to collaborate ...
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... cares for the offspring., Apart from the ones he sucks the ... is now creating a stir in the research world. The ... of organising childcare. In this fish species it is the father ... or more females and then looks after in a brood pouch ...
... 2009 Finishing your plate may soon take on a ... Montral School of Industrial Design, has fashioned edible plates that ... phase of her research, which has resulted in a book ... Edible, The Food as Material. "The idea of using ...
... Ga. University of Georgia scientists looking to understand ... found for the first time in plants an inverse ... has implications for diversity not only in plants, but ... published online in this week,s Proceedings of the ...
Cached Biology News:Brooding fishes take up nutrients from their own children 2Plate-eating good: Université de Montréal professor designs edible tableware 2Study finds new relationship between gene duplication and alternative splicing in plants 2Study finds new relationship between gene duplication and alternative splicing in plants 3
Mouse monoclonal [X223] to Lamin B1 + B2 - Nuclear Envelope Marker ( Abpromise for all tested applications). entrezGeneID: 4001 SwissProtID: P20700...
... (Human Exonic Evidence Based Oligonucleotide) Genome Set ... ) Genome Set contain a collection of ... constitutively expressed exons, allowing interrogation of thousands ... researchers at Stanford University and UCSF, the ...
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Biology Products: